U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Platinum-Resistant Ovarian Carcinoma

MedGen UID:
1642366
•Concept ID:
C4688007
•
Neoplastic Process
Synonym: Platinum-Resistant Ovarian Cancer

Definition

Ovarian carcinoma that progresses between one and six months of completing the last platinum therapy. [from NCI]

Professional guidelines

PubMed

Treatment Approaches for Platinum-Resistant Ovarian Cancer.
St Laurent J, Liu JF
J Clin Oncol 2024 Jan 10;42(2):127-133. Epub 2023 Nov 1 doi: 10.1200/JCO.23.01771. PMID: 37910841
Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review.
Richardson DL, Eskander RN, O'Malley DM
JAMA Oncol 2023 Jun 1;9(6):851-859. doi: 10.1001/jamaoncol.2023.0197. PMID: 37079311
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Tattersall A, Ryan N, Wiggans AJ, Rogozińska E, Morrison J
Cochrane Database Syst Rev 2022 Feb 16;2(2):CD007929. doi: 10.1002/14651858.CD007929.pub4. PMID: 35170751Free PMC Article

Recent clinical studies

Etiology

Potential efficacy of weekly low-dose administration of bevacizumab as a combination therapy for platinum-resistant ovarian carcinoma: a retrospective analysis.
Suminokura J, Miyamoto M, Yoshikawa T, Kouta H, Kikuchi Y, Hada T, Ishibashi H, Ito T, Iwahashi H, Kakimoto S, Suzuki R, Matsuura H, Kishimoto N, Takano M
BMC Cancer 2022 Feb 16;22(1):176. doi: 10.1186/s12885-022-09271-3. PMID: 35172766Free PMC Article
Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives.
Ventriglia J, Paciolla I, Pisano C, Cecere SC, Di Napoli M, Tambaro R, Califano D, Losito S, Scognamiglio G, Setola SV, Arenare L, Pignata S, Della Pepa C
Cancer Treat Rev 2017 Sep;59:109-116. Epub 2017 Jul 31 doi: 10.1016/j.ctrv.2017.07.008. PMID: 28800469
The use of Fluorouracil (5-FU) and leucovorin in women with heavily pretreated advanced ovarian carcinoma.
Peled Y, Levavi H, Krissi H, Weill Y, Sabah G, Eitan R
Am J Clin Oncol 2013 Oct;36(5):472-4. doi: 10.1097/COC.0b013e3182549399. PMID: 22706176
Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study.
Rose PG, Tian C, Bookman MA
Gynecol Oncol 2010 May;117(2):324-9. Epub 2010 Feb 24 doi: 10.1016/j.ygyno.2010.01.040. PMID: 20185168
Prognostic factors in platinum-resistant ovarian carcinoma treated with ifosfamide-etoposide.
Tropé CG, Kisic J, Vergote I
Eur J Gynaecol Oncol 2000;21(3):255-9. PMID: 10949388

Diagnosis

FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.
Corno C, Stucchi S, De Cesare M, Carenini N, Stamatakos S, Ciusani E, Minoli L, Scanziani E, Argueta C, Landesman Y, Zaffaroni N, Gatti L, Perego P
Biochem Pharmacol 2018 Jan;147:93-103. Epub 2017 Nov 16 doi: 10.1016/j.bcp.2017.11.009. PMID: 29155058
Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives.
Ventriglia J, Paciolla I, Pisano C, Cecere SC, Di Napoli M, Tambaro R, Califano D, Losito S, Scognamiglio G, Setola SV, Arenare L, Pignata S, Della Pepa C
Cancer Treat Rev 2017 Sep;59:109-116. Epub 2017 Jul 31 doi: 10.1016/j.ctrv.2017.07.008. PMID: 28800469
PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells.
Arrighetti N, Cossa G, De Cecco L, Stucchi S, Carenini N, Corna E, Gandellini P, Zaffaroni N, Perego P, Gatti L
Toxicol Appl Pharmacol 2016 Nov 1;310:9-19. Epub 2016 Aug 20 doi: 10.1016/j.taap.2016.08.005. PMID: 27554045
Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE).
Kurzeder C, Bover I, Marmé F, Rau J, Pautier P, Colombo N, Lorusso D, Ottevanger P, Bjurberg M, Marth C, Barretina-Ginesta P, Vergote I, Floquet A, Del Campo JM, Mahner S, Bastière-Truchot L, Martin N, Oestergaard MZ, Kiermaier A, Schade-Brittinger C, Polleis S, du Bois A, Gonzalez-Martin A
J Clin Oncol 2016 Jul 20;34(21):2516-25. Epub 2016 Jun 6 doi: 10.1200/JCO.2015.66.0787. PMID: 27269942
Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
Du P, Zhang X, Liu H, Chen L
DNA Cell Biol 2015 Jul;34(7):497-502. Epub 2015 May 5 doi: 10.1089/dna.2015.2805. PMID: 25941922

Therapy

Potential efficacy of weekly low-dose administration of bevacizumab as a combination therapy for platinum-resistant ovarian carcinoma: a retrospective analysis.
Suminokura J, Miyamoto M, Yoshikawa T, Kouta H, Kikuchi Y, Hada T, Ishibashi H, Ito T, Iwahashi H, Kakimoto S, Suzuki R, Matsuura H, Kishimoto N, Takano M
BMC Cancer 2022 Feb 16;22(1):176. doi: 10.1186/s12885-022-09271-3. PMID: 35172766Free PMC Article
Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m² versus 40 mg/m² in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial.
Motohashi T, Yabuno A, Michimae H, Ohishi T, Nonaka M, Takano M, Nishio S, Fujiwara H, Fujiwara K, Kondo E, Sugiyama T, Tabata T
J Gynecol Oncol 2021 Jan;32(1):e9. Epub 2020 Nov 10 doi: 10.3802/jgo.2021.32.e9. PMID: 33185050Free PMC Article
Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives.
Ventriglia J, Paciolla I, Pisano C, Cecere SC, Di Napoli M, Tambaro R, Califano D, Losito S, Scognamiglio G, Setola SV, Arenare L, Pignata S, Della Pepa C
Cancer Treat Rev 2017 Sep;59:109-116. Epub 2017 Jul 31 doi: 10.1016/j.ctrv.2017.07.008. PMID: 28800469
PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells.
Arrighetti N, Cossa G, De Cecco L, Stucchi S, Carenini N, Corna E, Gandellini P, Zaffaroni N, Perego P, Gatti L
Toxicol Appl Pharmacol 2016 Nov 1;310:9-19. Epub 2016 Aug 20 doi: 10.1016/j.taap.2016.08.005. PMID: 27554045
Paclitaxel (Taxol) therapy in ovarian carcinoma.
Caldas C, McGuire WP 3rd
Semin Oncol 1993 Aug;20(4 Suppl 3):50-5. PMID: 7688146

Prognosis

Potential efficacy of weekly low-dose administration of bevacizumab as a combination therapy for platinum-resistant ovarian carcinoma: a retrospective analysis.
Suminokura J, Miyamoto M, Yoshikawa T, Kouta H, Kikuchi Y, Hada T, Ishibashi H, Ito T, Iwahashi H, Kakimoto S, Suzuki R, Matsuura H, Kishimoto N, Takano M
BMC Cancer 2022 Feb 16;22(1):176. doi: 10.1186/s12885-022-09271-3. PMID: 35172766Free PMC Article
Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m² versus 40 mg/m² in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial.
Motohashi T, Yabuno A, Michimae H, Ohishi T, Nonaka M, Takano M, Nishio S, Fujiwara H, Fujiwara K, Kondo E, Sugiyama T, Tabata T
J Gynecol Oncol 2021 Jan;32(1):e9. Epub 2020 Nov 10 doi: 10.3802/jgo.2021.32.e9. PMID: 33185050Free PMC Article
Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives.
Ventriglia J, Paciolla I, Pisano C, Cecere SC, Di Napoli M, Tambaro R, Califano D, Losito S, Scognamiglio G, Setola SV, Arenare L, Pignata S, Della Pepa C
Cancer Treat Rev 2017 Sep;59:109-116. Epub 2017 Jul 31 doi: 10.1016/j.ctrv.2017.07.008. PMID: 28800469
PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells.
Arrighetti N, Cossa G, De Cecco L, Stucchi S, Carenini N, Corna E, Gandellini P, Zaffaroni N, Perego P, Gatti L
Toxicol Appl Pharmacol 2016 Nov 1;310:9-19. Epub 2016 Aug 20 doi: 10.1016/j.taap.2016.08.005. PMID: 27554045
Mitomycin C and 5-fluorouracil salvage chemotherapy in platinum-resistant ovarian carcinoma.
Benedetti Panici P, Greggi S, Scambia G, Salerno MG, Baiocchi G, Cento R, Mancuso S
Oncology 1992;49(3):183-7. doi: 10.1159/000227036. PMID: 1495744

Clinical prediction guides

Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study.
Vergote I, von Moos R, Manso L, Van Nieuwenhuysen E, Concin N, Sessa C
Gynecol Oncol 2018 Sep;150(3):471-477. Epub 2018 Jul 27 doi: 10.1016/j.ygyno.2018.07.018. PMID: 30060963
PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells.
Arrighetti N, Cossa G, De Cecco L, Stucchi S, Carenini N, Corna E, Gandellini P, Zaffaroni N, Perego P, Gatti L
Toxicol Appl Pharmacol 2016 Nov 1;310:9-19. Epub 2016 Aug 20 doi: 10.1016/j.taap.2016.08.005. PMID: 27554045
Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer.
Kavanagh JJ, Levenback CF, Ramirez PT, Wolf JL, Moore CL, Jones MR, Meng L, Brown GL, Bast RC Jr
J Hematol Oncol 2010 Mar 11;3:9. doi: 10.1186/1756-8722-3-9. PMID: 20222977Free PMC Article
Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma.
Sørensen P, Høyer M, Jakobsen A, Malmström H, Havsteen H, Bertelsen K
Gynecol Oncol 2001 Apr;81(1):58-62. doi: 10.1006/gyno.2000.6089. PMID: 11277650
Mitomycin-C plus a 3-day continuous intravenous infusion of 5-fluorouracil: an inactive salvage regimen for platinum-resistant ovarian carcinoma.
Reichman B, Markman M, Hakes T, Rubin S, Jones W, Curtin J, Barakat R, Almadrones L, Lewis JL Jr, Hoskins W
Gynecol Oncol 1993 Jul;50(1):30-3. doi: 10.1006/gyno.1993.1159. PMID: 8349161

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...